INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer

BACKGROUND: Resistance to HER2-targeted therapeutics remains a significant clinical problem in HER2+ breast cancer patients with advanced disease. This may be particularly true for HER2+ patients with basal subtype disease, as recent evidence suggests they receive limited benefit from standard of ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Moqing, Smith, Rebecca, Liby, Tiera, Chiotti, Kami, López, Claudia S., Korkola, James E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898494/
https://www.ncbi.nlm.nih.gov/pubmed/35248133
http://dx.doi.org/10.1186/s13058-022-01512-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898494/
https://www.ncbi.nlm.nih.gov/pubmed/35248133
http://dx.doi.org/10.1186/s13058-022-01512-4

Ejemplares similares